Bavarian Nordic AS - Company Profile

Powered by

All the data and insights you need on Bavarian Nordic AS in one report.

$195 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Bavarian Nordic AS Strategy Report

  • Understand Bavarian Nordic AS position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Bavarian Nordic AS: Overview

Select Item

Related keylists

Bavarian Nordic AS (Bavarian Nordic) is a vaccine company that develops, manufactures and commercializes vaccines for the prevention of life-threating diseases. The company develops its products using poxvirus-based technology platforms including modified vaccinia Ankara –Bavarian Nordic (MVA-BN). The company’s marketed products include JYNNEOS for smallpox and monkeypox; Encepur for tick-borne encephalitis; MVABEA for ebola; and Rabipur/RabAvert for rabbies. Its pipeline products are intended for the treatment of smallpox, COVID-19, respiratory syncytial virus, HER2- and brachyury-expressing cancers and Ebola infections. Bavarian Nordic has collaboration with the US government and various institutes, to develop its product candidates for the treatment of cancer and infectious diseases. It has a presence in the US, Denmark, Switzerland and Germany. Bavarian Nordic is headquartered in Hellerup, Denmark.

 Gain a 360-degree view of Bavarian Nordic AS and make more informed decisions for your business Gain a 360-degree view of Bavarian Nordic AS and make more informed decisions for your business Find out more
Headquarters Denmark
Address Philip Heymans Alle 3, Hellerup, 2900
Website www.bavarian-nordic.com
No of Employees 1,351
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange BAVA (CPH)
Revenue (2022) $445.4M 66% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ 25.3% (2022 vs 2021)
Market Cap* $1.9B
Net Profit Margin (2022) XYZ 55.0% (2022 vs 2021)
   
* As of and is in US$
View Bavarian Nordic AS financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Bavarian Nordic AS premium industry data and analytics

90+

Clinical Trials

Determine Bavarian Nordic AS go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

70+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Bavarian Nordic AS’s relevant decision makers and contact details.

70+

Catalyst Calendar

Proactively evaluate Bavarian Nordic AS’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

20+

Pipeline Drugs

Identify which of Bavarian Nordic AS’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

14+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

7

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

6

Marketed Drugs

Understand Bavarian Nordic AS’s commercialized product portfolio to stay one step ahead of the market.

5

Sales & Consensus Forecasts

Understand the current and future drug revenue for Bavarian Nordic AS and assess market opportunity for new entrants with patient population 8-year forecasts.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Bavarian Nordic AS’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Jynneos/Imavanex- Smallpox and Monkeypox Vaccine Jynneos
Rabipur/Rabavert- Rabies Vaccine Imvanex
Encepur- Tick-Borne Encephalitis Vaccine Imvamune
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Bavarian Nordic AS portfolio and identify potential areas for collaboration Understand Bavarian Nordic AS portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Acquisitions/Mergers/Takeovers In May, the company acquired travel health business portfolio from Emergent BioSolutions Inc.
2022 Contracts/Agreements In December, the company entered into an agreement with the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense for the advanced development of MVA-BN WEV.
2022 Others In September, the company announced the dosing of the first subject in the Phase 3 clinical trial of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 booster vaccine candidate.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Bavarian Nordic AS Moderna Inc BioNTech SE Novavax Inc Icosavax Inc
Headquarters Denmark United States of America Germany United States of America United States of America
City Hellerup Cambridge Mainz Gaithersburg Seattle
State/Province - Massachusetts Nordrhein-Westfalen Maryland Washington
No. of Employees 1,351 3,900 4,530 1,992 60
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Luc Debruyne Chairman Executive Board 2023 60
Paul Chaplin Chief Executive Officer; President Senior Management 2014 56
Henrik Juuel Chief Financial Officer; Executive Vice President Senior Management 2018 58
Russell Thirsk Chief Operating Officer; Executive Vice President Senior Management 2022 55
Anu Helena Kerns Chief People Officer; Executive Vice President Senior Management 2020 51
Non Dignissim Eros Proin vel Convallis 2023 XY
Non Dignissim Eros Proin vel Convallis 2023 XY
Non Dignissim Eros Proin vel Convallis 2023 XY
Gain insight into Bavarian Nordic AS key executives to enhance your sales strategy Gain insight into Bavarian Nordic AS key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward